The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NBY | +81.13% | -99.83% | -72.14% | -100% |
| S&P | +11% | +85.61% | +13.15% | +330% |
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.52M | -78.7% |
| Gross Profit | $0.04M | -97.4% |
| Gross Margin | 8.06% | -57.2% |
| Market Cap | $7.69M | 245.4% |
| Market Cap / Employee | $0.55M | 0.0% |
| Employees | 14 | -46.2% |
| Net Income | -$1.33M | -10.0% |
| EBITDA | -$1.14M | -7.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.31M | 197.6% |
| Accounts Receivable | $0.37M | -47.7% |
| Inventory | 0 | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.41M | -50.7% |
| Short Term Debt | $0.57M | 28.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -215.92% | -96.4% |
| Return On Invested Capital | -332.18% | -101.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.84M | 10.8% |
| Operating Free Cash Flow | -$1.84M | 10.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.82 | -13.99 | 0.36 | 1.76 | -278.34% |
| Price to Sales | 0.30 | 0.43 | 0.71 | 2.66 | 1064.20% |
| Price to Tangible Book Value | 1.82 | -13.99 | 0.36 | 1.76 | -278.34% |
| Enterprise Value to EBITDA | -3.50 | 1.65 | 0.57 | -9.25 | 219.22% |
| Return on Equity | -452.7% | -235.5% | -431.6% | -587.6% | 138.35% |
| Total Debt | $1.67M | $1.13M | $1.04M | $0.97M | -23.14% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
